Wall Street equity research analysts tracking Coya Therapeutics maintain optimistic 12-month consensus price targets. Projections from covering institutions range from a low of $12.00 up to a high of $18.00, resulting in an average consensus target sitting around $15.00 per share, reflecting substantial predicted upside from its current market trading valuation.